Thanks to everyone who helped with this investigation. The litigation is ongoing and any substantial updates will be posted to this page. You can view our active list of investigations here or learn why you don’t need to join a class action to be included in any potential settlement. You can also sign up for our newsletter for the latest updates. Please keep in mind that the information on this page is for reference only and was posted when the investigation began.
At A Glance
This Alert Affects:
Anyone who purchased and took Zantac.
What’s Going On?
Class action lawsuits have been filed alleging that Zantac exposes users to unsafe levels of NDMA, a chemical that the World Health Organization has described as “clearly carcinogenic.”
How a Class Action Can Help
A class action lawsuit can help people who purchased Zantac get their money back for the medicine and require a full recall for the drug or an update to its labeling.
Class action lawsuits have been filed alleging that Zantac exposes users to unsafe levels of a probable carcinogen and that the manufacturers knew about the risk but failed to disclose it.
Why Were Lawsuits Filed?
The first class action was filed shortly after online pharmacy Valisure notified the FDA that it found “dangerous levels” of a probable carcinogen known as n-nitrosodimethylamine (NDMA) in “all lots tested, across multiple manufacturers of ranitidine products,” including Zantac.
Valisure’s testing detected 2.5 nanograms of NDMA – more than 26,000 times the FDA’s daily permissible intake of NDMA – per 150mg tablet of Zantac.
The lawsuits claim that the FDA “has done very little to protect the American public with respect to Zantac” and that its announcement “downplays” the issue.
Zantac and Cancer Risk: Did the Companies Know?
It is being alleged that manufacturers Sanofi and Boehringer Ingelheim Pharmaceuticals knew or had reason to know that Zantac produces high quantities of NDMA when ingested. Several scientific studies have been published showing that ranitidine – the active ingredient in Zantac – forms NDMA when placed in water and that users of the drug have “a 400-fold increase of NDMA concentration in their urine,” according to the suits.
Despite this research, neither manufacturer alerted the public on the drug’s label or through any other means.
The suits attest that consumers would never have purchased or taken the drug had they known of its risks.
How Can a Class Action Lawsuit Help?
A successful class action lawsuit can help people who used Zantac get back the money they spent on the drug. One plaintiff in the lawsuit, a regular user of Zantac, claims she spent approximately $800 on the medication.
The manufacturers could also be required to update labeling on the drug or to stop selling it altogether.
Is Zantac Being Recalled?
In late September 2019, Sandoz Inc. voluntarily recalled 14 lots of ranitidine hydrochloride capsules – a generic version of Zantac available as a prescription – that were found to contain “elevated” levels of NDMA. Apotex Corp. also announced it would be recalling all ranitidine tablets as a precautionary measure.